Treg and T-cell phenotype changes during ruxolitinib treatment. (A-B) Shown are a representative flow cytometry plot and the absolute numbers of Treg cells in the spleens of animals on the indicated time points (days 8, 14, 29) after allo-HCT from vehicle or ruxolitinib-treated mice. Data from 2 independent experiments are pooled. (C-D) Shown are a representative flow cytometry plot (ileum) and the percentage of Treg cells in the ileum and colon of animals on the indicated time points after allo-HCT from vehicle or ruxolitinib-treated mice. Data from 2 independent experiments are pooled. (E-F) Shown are a representative flow cytometry plot (ileum) and the percentage of CD4⁺IFN-γ⁺ cells in the ileum of animals on the indicated time points after allo-HCT from vehicle or ruxolitinib-treated mice. Data from 2 independent experiments are pooled. (G) CD4⁺CD62L⁺ naïve T cells (BALB/c) were exposed to BM-derived DC (C57BL/6) preactivated with 20 ng/mL LPS. The percentage of CD4⁺FoxP3⁺ cells of all CD4⁺ cells is shown for different concentrations of ruxolitinib. One representative experiment of 3 is shown. (H) CD4⁺ T cells (BALB/c) were exposed to BM-derived DC (C57BL/6) preactivated with 20 ng/mL LPS. The percentage of CD4⁺IFN-γ⁺ cells of all CD4⁺ cells is shown for different concentrations of ruxolitinib. One representative experiment of 3 is shown.